In March 2008, Farmanguinhos/Fiocruz successfully registered ASMQ in Brazil. The co-formulation was used by Brazilian authorities and the Malaria Programme for a large intervention study, which included over 31,000 patients, with remarkable positive results. [see more details on the study, PDF, 85KB]

The ASMQ FDC registration process is underway in 3 additional malaria endemic countries in Latin America: Bolivia, Peru and Venezuela.
An active Pharmacovigilance plan in being put in place in Brazil.

Farmanguinhos/Fiocruz with support from DNDi committed to a technology transfer to the Indian manufacturer, Cipla, in order to facilitate its future availability in Southeast Asia. This transfer has been successfully achieved and the registration lots have been manufactured by Cipla at the end of 2009 - beginning of 2010.

In December 2011, ASMQ was registered in India and in Malaysia in April 2012.

A comparison of ACTs has been performed in Myanmar between December 2008 and March 2009. This important study showed very favorable results for the FDC. [see more details on the study, PDF, 11KB]
A WHO study on 45 patients in ongoing in Cambodia, showing overall favorable results.
A phase III trial is ongoing in Thailand on 1000 pregnant women comparing the efficacy, safety and pharmacokinetics of ASMQ FDC and artmether-lumefantrine.